1	<b>Disrupting Cdc42</b>	<b>Activation-Driven</b>	<b>Filopodia Forma</b>	tion with Low-I	ntensity Ultrasound and

# 2 Microbubbles: A Novel Strategy to Block Ovarian Cancer Metastasis

- 3 Xiaoying Li<sup>1</sup>, Chengwei Tan<sup>2</sup>, Xiuxiu Fu<sup>2</sup>, Jian Qiu<sup>3</sup>, Wanting Shen<sup>2</sup>, Zhikang Xu<sup>2</sup>, Xiaodong Wu<sup>2</sup>,
- 4 Yiting Zhou<sup>4 $\boxtimes$ </sup>, Xiao Li<sup>2 $\boxtimes$ </sup>, Litao Sun<sup>1 $\boxtimes$ </sup>, Jiale Qin<sup>2,5,6 $\boxtimes$ </sup>
- 5
- 6 <sup>1</sup> Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital
- 7 (Affiliated People's Hospital), Hangzhou, 310006, China
- 8 <sup>2</sup> Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China
- <sup>9</sup> <sup>3</sup> Department of Obstetrics and Gynaecology, Huzhou Central Hospital, Affiliated Central Hospital
- 10 Huzhou University, Huzhou, 313000, China
- <sup>4</sup> Department of Orthopaedic Surgery and Department of Biochemistry of the Second Affiliated
- 12 Hospital, Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310058, China,
- 13 <sup>5</sup> Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases,
- 14 Hangzhou, 310006, China
- 15 <sup>6</sup> Zhejiang Provincial Clinical Research Center for Gynecological and Obstetrical Diseases,
- 16 Hangzhou, 310006, China
- 17
- 18 ⊠corresponding authors: qinjiale@zju.edu.cn, sunlitao@hmc.edu.cn, 5198008@zju.edu.cn, and
   19 zhouyt@zju.edu.cn
- 20 21

24

31 Abstract:

32 **Introduction:** Metastasis is a leading cause of mortality and treatment failure in ovarian cancer. 33 However, effective strategies to target this process remain limited. Low intensity ultrasound (LIUS) 34 and microbubbles (MBs) have shown promise in blood-brain barrier opening and drug delivery. 35 However, the role in tumor metastasis remains unexplored. Objectives: To investigate the potential 36 of LIUS and MBs in inhibiting ovarian cancer metastasis and the underlying mechanisms. Methods: 37 Based on the results of cell experiments to identify the optimal parameters, three ditinct mouse 38 models-orthotopic, intraperitoneal metastatic, and hematogenous metastatic nude mouse models-39 were established to evaluate the spatiotemporal effects of LIUS and MBs on ovarian cancer 40 metastasis. Filopodia and lamellipodia formation in cancer cells was assessed using both 41 immunofluorescence and scanning electron microscopy. Additionally, the expression levels of total 42 Cdc42 and active Cdc42 were measured. Finally, the constitutively active Cdc42 rescue experiment 43 was performed. Results: Our results demonstrated that LIUS and MBs significantly suppressed 44 metastasis in orthotopic ovarian cancer, as well as individually reducing both intraperitoneal and 45 hematogenous metastatic potential in treated cells. This treatment was associated with a reduction 46 in the length and number of filopodia, while the number of lamellipodia remained unaffected. 47 Notably, this is the first study conducted at the molecular level to demonstrate that the disturbing of 48 filopodia by LIUS and MBs is mediated through the modulation of Cdc42 activation. In this, the 49 inhibitory effect of LIUS and MBs on both filopodia formation and the metastatic potential of 50 ovarian cancer cells was reversed by the overexpression of constitutively active Cdc42. 51 Conclusion: Our findings indicated that LIUS and MBs possesses the capacity to inhibit tumor 52 metastasis via disturbing the cytoskeletal remodelling of filopodia. This study provides novel 53 insights into the mechanisms underlying the metastatic inhibition by LIUS and MBs, expanding the 54 understanding of this technique beyond its established uses.

- 55
- 56

Keywords: Low intensity ultrasound, ovarian cancer, metastasis, filopodia, Cdc42

57

58

# 60 1. Introduction

61 The considerable mortality rate of ovarian cancer, having a five-year survival rate of 30-50%, poses 62 a severe threat to women's health [1, 2]. Standard first-line therapy involves cytoreductive surgery 63 in conjunction with platinum-based chemotherapy and maintenance therapy (NCCN Guidelines ®) 64 [3]. However, the presence of unresectable lesions during debulking surgery, as opposed to when 65 complete resection is possible, leads to higher rates of local and distant metastasis and recurrence. 66 Both aspects of metastasis serve as independent risk factors for poor prognosis [2, 4]. In such cases, 67 the development of effect adjuvant therapy to inhibit the metastasis of these unresectable residual 68 lesions is suggested to represent the most direct and effective approach.

69 Ultrasound therapy strategies that harness the mechanical activity of ultrasound stimulate the 70 microbubbles (MBs) for bioeffects are being actively developed [5]. Gas-filled MBs are highly 71 sensitive to changes in pressure, due to this, their volume can change rapidly and dramatically when 72 they are exposed to ultrasonic waves. These volume changes act on cells or tissues can induce 73 mechanical effects, chemical effects, and thermal effects [5]. It is worth noting that the biological 74 effects induced by different ultrasonic parameters are also very different. Low intensity ultrasound 75 (LIUS) interaction with MBs minimize thermal effects, and the mechanical effects caused by them 76 are mainly cavitation and secondary effects, including direct impingement, ballistic motion, and 77 microstreaming [5, 6]. Furthermore, the allure of LIUS therapy stems from its ability to treat deeply 78 situated tumors within the body effectively without causing significant harm to the overlying skin 79 and adjacent normal tissues [7]. The most developed application of LIUS stimulated MBs is drug 80 delivery, as the bioeffects caused by the interaction between LIUS and MBs are gradually studied, 81 increasing attention is being paid to their role in tumor therapy.

LIUS combined with MBs, as a potential adjuvant therapy, is known to provide an additional suppressive impact against tumor metastasis [8]. An extensive array of laboratory animal studies have demonstrated that the amalgamation of LIUS and MBs with chemotherapy [8, 9], immunotherapy [10], or drug carriers [11], can thereby significantly curtail tumor metastasis. Clinical trials have also been implemented utilizing LIUS-triggered MBs to augment chemotherapy for pancreatic cancer [12, 13] and gastrointestinal malignancies [14]. In these examples tumor progression was restricted to the original sites with no emergence of new lesions [12-14]. Another 89 recent *in vitro* study has also provided new evidence that LIUS can impede the collective migration 90 of pancreatic cancer cells [15]. Unfortunately, there have been no *in vivo* studies to date that examine 91 the direct inhibitory effects or mechanisms of LIUS combined with MBs on tumor metastasis. In 92 this study, we explored the inhibitory effect of LIUS and MBs on ovarian cancer metastasis *in vivo* 93 via the constructing orthotopic ovarian cancer, peritoneal metastasis, and hematogenous metastasis 94 nude mouse models.

95 At the mechanistic level, similar to other cancers, ovarian cancer metastasis involves a series 96 of multistep cellular processes known as the invasion-metastasis cascade [16, 17]. Filopodia, at the 97 leading edge of tumor cells, play an important role in this by determining the direction of cell 98 movement in the initiation of tumor cell migration [17, 18]. The development and protrusion of 99 filopodia towards signaling sources are regulated by dynamic processes of cytoskeletal remodeling 100 which are regulated by the small GTPase Cdc42 signaling pathway. The activation of Cdc42 is due 101 to the phosphoric acid group of GTP binding to the carboxyl group of Cdc42 protein. After this 102 Cdc42 interacts with downstream effector proteins to direct the assembly of actin-based structures 103 and stimulate the formation of filopodia [19-21]. Here, we speculate that the diminished capacity 104 for cellular migration and invasion can be attributed to the reduction in filopodia development 105 resulting from LIUS-triggered MBs-induced inhibition of Cdc42 activity.

106 In summary, elucidating the inhibitory effects of LIUS combined with MBs on ovarian cancer 107 metastasis and its underlying mechanisms will provide a scientific basis for considering LIUS as an 108 adjuvant therapeutic strategy for the prevention and treatment of ovarian cancer metastasis.

109 2. Materials and methods

110 2.1 Cells and reagents

111 The human epithelial ovarian cancer lines SKOV3 (CS-K8752X), HO8910PM (CS-K8752X) and 112 ovarian epithelial cell line IOSE80 (CS-K88024X) that has been immortalized but is not 113 tumorigenic were purchased from the Shanghai C-reagent Biotechnology Co. Ltd. (Shanghai, 114 China). SKOV3, HO8910PM, and IOSE80 were grown in a mixture of RPMI 1640 medium (BC-115 M-017, Biochannel, China), which were supplemented with 10% fetal bovine serum (FBS) (BC-116 SE-FBS01, Biochannel, China) and 1% streptomycin and penicillin. By transducing luciferase117 expressing lentivirus constructs of SKOV3-luc cells (Shanghai C-reagent Biotechnology Co. Ltd.,

118Shanghai, China) were cultured in RPMI 1640 completed medium. Cell culturing was performed in

an atmosphere of 5%  $CO_2$  at 37°C.

## 120 *2.2 Ultrasound treatment procedure*

121 A single element planar ultrasound transducer, driven by a power source host, was used to generate 122 ultrasound pulses (Chongqing Ronghai Ultrasound Medical Engineering Research Center Co., Ltd.). 123 The transducer had a center frequency of 1.03MHz, a diameter of 35mm, and was held in place 124 using a gripping device. The pulse repetition frequency was 2360Hz. Three minutes of ultrasound 125 were applied to cells suspensions (duty cycle = 20%). The acoustic contrast agent SonoVue® 126 (Bracco, Milan, Italy) as MBs was used to induce cavitation. The SonoVue® MBs was prepared as 127 a suspension in-situ via mixing the powder with 5ml of sterile saline in accordance with the 128 manufacturer's instructions. Our MB/cell ratio was maintained at around 100/1 according to Song 129 et al. 's study [22]. For exposure to LIUS and MBs treatment, the sample cells were plated in 35mm 130 dish and the dish was aligned axially with the ultrasound transducer.

# 131 2.3 Lentiviruses, plasmids, and transfection

Lifeact-mcherry overexpression lentivirus (Ubi-MCS-SV40-puromycin) was synthesized by
Genechem (China). Transfection was performed with Lipofectamine 3000 (L3000015, Thermo
Fisher Scientific, USA). The pXJ40-HA-Cdc42CA (constitutively activate Cdc42, G12C mutation)
was received as a kind gift from Prof. Yiting Zhou (Zhejiang University, China). An empty pXJ40HA vector was used as a control. The plasmids were transfected using Lipofectamine 3000
(L3000015, Thermo Fisher Scientific, USA).

138 2.4 Cell viability assays

139 Based on the manufacturer's instructions, the viability of SKOV3 was assessed using the Calcein-

140 AM/ Propidium Iodide (PI) double staining kit (40747ES76, Yaseen, China) [23]. Specifically, 5

- 141 µL of Calcein-AM (2 mM) and 15 µL of PI (1.5 mM) were diluted in 5 mL of 1× assay buffer and
- subsequently applied to SKOV3 cells following the LIUS and MBs treatment. After a 30-minute
- 143 incubation period, phosphate-buffered saline (PBS) was used to rinse the stained cells and washed

twice before flow cytometry detection.

## 145 *2.5 Wound healing assay*

146 Our wound healing assays were conducted using 6-well plates with 4 well culture insert (#80469, 147 Ibidi, Germany) [24]. The cells were cultured by seeding them into above plates after with or without 148 LIUS and MBs treatment, the cell concentration was adjusted to 110 µl of cell suspension (SKOV3 149  $3 \times 10^5$  cells/ml, HO8910PM  $1 \times 10^6$  cells/ml). A culture of the cells was performed overnight, and 150 the inserts were removed. Following the removal of non-viable cells using PBS, the remaining cells 151 were maintained in RPMI 1640 culture medium with 2% FBS. Each wound was documented 152 through photography (CKX53, Olympus, Japan) at the specified time points. The wound closure 153 rate was subsequently calculated using Image J software.

## 154 2.6 Transwell migration and invasion

For transwell assays, 6.5mm-diameter transwell plate inserts with 8 µm pore size (#3421, Corning, 155 156 NY, USA) were used [25]. An upper chamber of a transwell plate was seeded with a serum-free 157 medium containing 200 microliters of cell suspension (SKOV3 5  $\times$  10<sup>5</sup> cells/ml, HO8910PM 2.5  $\times$ 158 10<sup>6</sup> cells/ml) with or without LIUS and MBs. Lower chambers were enriched with 10% FBS in 159 500ul RPMI 1640 medium. Cells were then cultured for 24 hours as described above. A matrigel-160 coated (#356234, Corning, USA) upper chamber was used for invasion experiments. The cells on 161 the inner side of the upper chamber were then removed using cotton swabs, and 4% 162 paraformaldehyde was used to fix the cells on the upper chamber migrated to lower surface of the 163 membrane and stained them with crystal violet (BL539A, Biosharp, Beijing, China) for observation 164 and counting under a microscope (CKX53, Olympus, Japan). Number of cells that migrated was 165 counted in 5 different fields and results were determined from three repeated experiments.

166 2.7 Western blot

We performed Western blot analysis in accordance with the previous description [26]. A cocktail of protease inhibitors has been added to RIPA buffer (P0013, Beyotime, China) to facilitate cell lysis. The samples were subsequently run on 4-20% gels (IPVH00010, GenScript, China), and then the proteins were transferred onto PVDF membranes (IPVH00010, Millipore, USA). The membranes were blocked with 5% non-fat milk and then incubated overnight at 4°C with primary
antibodies. Thereafter, secondary antibodies conjugated to HRP were incubated for 1 hour at room
temperature. Chemiluminescence reagents were used to visualize Western blots analysis
(WBKLS0100, Millipore, USA). Proteins were detected using Azure biosystems (Azure 500, USA).
Primary antibodies used were anti-Cdc42 (1:10000; AB187643, Abcam, USA) and anti-GAPDH
(1:10000; AB181602, Abcam, USA). Secondary antibodies were purchased from Biodragon
(1:10000, BF03116, China).

178 2.8 Live-Cell Imaging

179 SKOV3-lifeact-mcherry cells fluorescently labeled with red F-actin were used for time-lapse microscopy. The cells were incubated in a 6-well plate at a suitable density the night before 180 181 observation, and the nuclei were labeled with Hoechst (33342, Thermo Fisher Scientific, USA). 182 Observations were made immediately after LIUS and MBs treatment and continued for 6 h, with 183 time-lapse images were acquired at 5 min per frame. The sites of all cells were recorded and used 184 to plot trajectories. The Imaris software was used to calculate the accumulated distance, Euclidean 185 distance, average cell velocity, and directionality for each group. The Euclidean distance is defined as the distance between first and last position of cell motility. The accumulated distance is the total 186 187 length of the cell's trajectory. The average cell velocity on an orbit is divided by the cumulative 188 distance divided by the time it takes the cell to travel that distance. Cell movement directivity is 189 defined as the ratio of Euclidean distance to cumulative distance. The persistence of cell movement 190 in a preferred direction is assessed by calculating the directionality of each cell. A directionality 191 value of 1 indicated that the cells moved in a straight line.

- 192 2.9 Scanning electron microscopy
- 193 Scanning electron microscope (SEM) observations were performed on Nova Nano SEM (NNS-450).

194 SEM measurements were conducted at 500 kV, with a resolution of up to 1.4nm. SKOV3 cells were

- analyzed using SEM after being treated with ultrasonic cavitation 6h or untreated.
- 196 *2.10 Immunofluorescence assay*
- 197 SKOV3 cells  $(1 \times 10^5)$  were seeded in 35mm glass-bottom dish (Biosharp, China). After LIUS and
- MBs treatment, cells were washed with PBS 3 times, and fixed with 4% paraformaldehyde for 10

199 min. Then the cells were permeated by 0.3% Triton X-100 for 10 min. After the cells were sealed

200 by 5% BSA for 30 min, they were incubated at 4°C overnight with F-actin antibodies (ab205,

201 Abcam, USA). The secondary antibody was used Rhodamine-linked Anti-mouse IgG (SA00007-1,

202 Proteintech, Chian). Following 1 h of incubation at room temperature and then stained with DAPI

- 203 antifade solution (C1006, Beyotime, China). A confocal microscope (Leica, Germany) was used to
- 204 capture fluorescence images.

205 2.11 RNA Sequencing

206 RNA sequencing was conducted by Shanghai Model Organisms Center (Shanghai, China). In 207 summary, the collected SKOV3 cells which after treated with ultrasonic cavitation 3h, 6h, 12h, and 24h and non-treatment RNA isolation utilizing TRIzol reagent (Invitrogen). Subsequently, 208 209 ribosomal RNA (rRNA) was removed from total RNA using the TruSeq Stranded Total RNA with 210 Ribo-Zero Gold kit, followed by reverse transcription to synthesize complementary DNA (cDNA). 211 The purified DNA was then amplified through polymerase chain reaction (PCR) and subjected to 212 quality assessment using the Agilent Bioanalyzer 2100 system (Agilent Technologies, USA). 213 Finally, an Illumina sequencer was utilized for sequencing.

214 2.12 Proteomics

A proteomics study was conducted by Oebiotech LTD (Shanghai, China) which contained normalized protein expression data in the mass spectrometry from the SKOV3 cell after LIUS and NBs treatment 6h, 12h and 24h and non-treatment.

218 2.13 Cdc42 Pull-Down activation assay

Active Cdc42 level was assessed by a Cdc42 Pull Down activation assay kit (#80701, NewEast Biosciences, PA, USA) which selectively recognizes Cdc42GTP [27]. SKOV3 cells were post treated by ultrasonic cavitation for 6h and subsequently collected and subjected to lysis. Cellular protein lysates underwent incubation with a monoclonal antibody specific to active Cdc42 (#26905, NewEast Biosciences, PA, USA), which selectively recognizes Cdc42GTP. The Cdc42GTP complex was then pulled down using protein A/G agarose (#30301, NewEast Biosciences, PA, USA) at 4 °C for 1 hour with agitation by sample mixer. Following centrifugation, washing, and resuspension in 2x SDSPAGE protein loading buffer. After boiling for 5 minutes, the lysateantibody complex was eluted from the agarose. The proteins were then analyzed through immunoblotting using an anti-Cdc42 antibody (#21010, NewEast Biosciences, PA, USA) after electrophoresis and membrane transfer.

230 2.14 Animal studies

The animal experiments in this study were reviewed and approved by the ethics committee of the
Zhejiang Chinese Medical University Laboratory Animal Research Center (Hangzhou, China).
Institutional and Animal Care and Use Committee guidelines were followed in the care and handling
of the animals (No. 20230911-11). The 4-week-old BALB/c female nude mice were purchased from
Shanghai BK Lab. Animal Research Center (Shanghai, China).

236 For orthotopic ovarian cancer nude mouse models,  $2 \times 10^6$  SKOV3-luc cells were injected into the 237 right ovary of the nude mice. In vivo imaging system (IVIS) imaging was performed 10 days after 238 SKOV3-luc cell injection. The mice were randomly divided into two groups (one group for LIUS + 239 MBs treatment, the other group untreated), with each group consisting of 6 mice. Ultrasonic 240 cavitation treatment group followed with acoustic intensity =  $0.6 \text{ W/cm}^2$ ; duty cycle =20%; 241 exposure time = 5 min; caudal vein administration of 200uL microbubbles per mouse, and with 242 treatment administered every other day. On Day 31, the mice were killed, and tumor tissues were 243 harvested.

244 For nude mice of the ovarian cancer, peritoneal metastasis, and hematogenous metastasis models, 245 those were injected SKOV3-luc cells in the abdomen or caudal vein. In these  $2 \times 10^6$  SKOV3-luc 246 cells were subjected to ultrasonic cavitation treatment (acoustic intensity =  $0.6 \text{ W/cm}^2$ ; duty cycle 247 =20%; exposure time = 3 min, maintaining the microbubble /cell ratio at around 100/1) which is the 248 ultrasonic cavitation group. The nude mice of the control group were injected  $2 \times 10^6$  SKOV3-luc 249 cells without any treatment in the abdomen or caudal vein. 6 mice were treated in each group. IVIS 250 imaging was then performed on 10, 17, 24, 31 days. On Day 31, the mice were killed, and tissues 251 were harvested.

Animals were monitored once a week using the IVIS Spectrum in vivo imaging system (PerkinElmer) for luciferase signal detection. IVIS images were captured to assess the bioluminescence signal. The specific procedure is as follows: Nude mice were intraperitoneally 255 injected with the luciferase D-luciferin potassium luminescent substrate (122799, PerkinElmer,

USA) at a concentration of 30 mg/mL, with each mouse receiving 100 µL. Five minutes post-

257 injection, the mice were placed in a transparent plexiglass anesthesia chamber (3.5% isoflurane).

258 After achieving anesthesia, the mice were transferred to the imaging system. Automatic exposure is

used for imaging.

260 2.15 Statistical analysis

This study was conducted using Graphpad Prism 10.0 for statistical analysis (GraphPad Software, USA). Data is expressed as mean and standard deviation. The difference between groups was analyzed statistically using Student's t-tests. For multiple comparisons, one-way analysis of variance (ANOVA) was used. If the data did not follow a normal distribution, non-parametric tests were applied as appropriate. Statistics were considered significant if the difference was p < 0.05.

#### 266 **3. Results**

## 267 3.1 LIUS combined with MBs reduced ovarian cancer cell migration and invasion

268 Based on the significant differences in cell characteristics (e.g., stiffness) and morphology (e.g., 269 nuclear size) between cancer and normal cells, as well as the distinctive spectral differences in their 270 inherent vibration frequencies, selectively targeting cancer cells for disruption using LIUS has been 271 proposed [28]. Our previous research found that Low-Intensity Focused Ultrasound induced MBs 272 could reverse paclitaxel resistance in ovarian cancer via inhibiting autophagy [29]. The degree of 273 lethal cell injury induced by LIUS and MBs correlated with exposure intensity [30, 31]. In this 274 study, cell viability rates were measured by the flow cytometry analyses after LIUS and MBs on 275 normal ovarian epithelial cells (IOSE80 cells). Results showed that the cell mortality rate began to 276 exceeded 10% when the LIUS intensity was 1.8 W/cm<sup>2</sup>. Conversely, when the LIUS intensity was 277 below 1.0 W/cm<sup>2</sup>, no significant difference in cell mortality was observed before and after LIUS 278 and MBs treatment (Fig. 1A). To avoid damaging non-cancerous cells, tissues, or organs, it is 279 therefore becoming necessary to choose an appropriate ultrasonic intensity with a mortality rate of 280 less than 10% [32-34]. Wound healing assays were then used to observe the inhibitory levels at 281 varying LIUS (0.2 W/cm<sup>2</sup> -1.0W/cm<sup>2</sup>) and MBs upon the migration of ovarian cancer SKOV3 (Fig. 1B) and HO8910PM (Fig. S1). The inhibitory effect of LIUS combined with MBs on SKOV3 cell 282

283 migration was found to be intensity-dependent. At an ultrasound intensity of 0.2 W/cm<sup>2</sup>, no 284 significant difference in cell migration was observed between the LIUS + MBs-treated and untreated 285 groups. However, at 0.6 W/cm<sup>2</sup>, a clear inhibitory effect on ovarian cancer cell migration was 286 observed. The inhibitory effect was even more pronounced at an intensity of 1.0 W/cm<sup>2</sup> (Fig. 1B). 287 In the case of HO8910PM cells, no significant inhibition of cell migration was observed with LIUS 288 + MBs at 0.2 W/cm<sup>2</sup>. At 0.6 W/cm<sup>2</sup>, a significant reduction in cell migration was observed, and a 289 similar effect was noted at 1.0 W/cm<sup>2</sup>, and no obvious ultrasonic intensity dependence was shown 290 (Fig. S1). This suggests that the inhibitory effect of LIUS combined with MBs on ovarian cancer 291 cells exhibits cellular heterogeneity. Further, the transwell assay was employed to further explore 292 the influence of LIUS with 0.6 W/cm<sup>2</sup> on migration and invasion of ovarian cancer cells. Results 293 showed a clear decrease in migratory and invasion capacity of SKOV3 (Fig. 1C, D) and HO8910PM 294 (Fig. S2A, B) cells that had received LIUS and MBs treatment.

295 To observe the real-time inhibitory effect of LIUS and MBs treatment on single cell motility, 296 time-lapse microscopy was employed to capture the trajectory of SKOV3 cell movement (Fig. S3A). 297 To measure these differences in cell migration, individual cells were tracked for 6 hours, and 298 representative migration tracks of 180 cells from both the untreated and treated (LIUS + MBs) 299 groups were recorded. Subsequently, a quantitative analysis of these cell migration patterns was 300 performed to characterize their migratory properties. Cells treated with LIUS and MBs showed 301 significantly lower migration velocities and shorter migration distances (including accumulated 302 distance and Euclidean distance (Fig. S3B-D)). Additionally, following LIUS + MBs treatment, the 303 orientation of the cells was reduced (Fig. S3E). Here, 'orientation' refers to the persistence of 304 movement in a preferred direction. Tumor cell directional movement plays a crucial role in 305 metastasis, influencing the spread and growth of cancer [35]. These results suggested that LIUS 306 combined MBs not only affected cell motility but may also interfered with the direction of tumor 307 cell movement. Markedly decreased cell migration and invasion was noted after LIUS and MBs 308 treatment, compared to that of non-treatment group. Considering the above results, we chose the 309 minimum effective LIUS intensity 0.6 W/cm<sup>2</sup> for the subsequent in vivo experiments.

310 3.2 LIUS combined with MBs reduced the tumorigenicity and metastasis in an orthotopic ovarian
311 cancer mouse model

312 The orthotopic mouse tumor model implants tumor cells or tissue into the correct anatomical site, 313 closely replicating the tumor's natural growth environment. This approach more accurately reflects 314 the biological characteristics of tumors, and since tumor growth and metastasis in this model 315 resemble human conditions, it offers clinically relevant insights for evaluating therapeutic efficacy 316 [36]. To examine the effect of LIUS and MBs treatment on tumor tumorigenicity and metastasis in 317 vivo, an ovarian cancer orthotopic transplantation model was constructed (Fig. 2A). To monitor 318 tumor growth of ovarian cancer, an in vivo imaging system (IVIS) was used to visualize fluorescence 319 intensity (Fig. 2B). Subsequently, the fluorescence intensity was quantified. Building upon previous 320 research on LIUS with MBs methods [22, 37], this study adopts a regimen of 10 sessions, each 321 lasting 5 minutes, conducted every other day using LIUS and MBs. As displayed in Fig. 2C, the 322 average total luminescence flux for treated mice was significantly decreased after treating with 323 LIUS and MBs 10 sessions of 5 minutes every other day. There was no significant difference in 324 fluorescence intensity between the LIUS + MBs treated group and the control (untreated) group on 325 days 10, 17, and 24 after tumor inoculation. This suggested that LIUS + MBs therapy may require 326 multiple repetitions. Abdominal metastases in mice were then assessed through macroscopic 327 observation, and the number of metastases was significantly less in the LIUS and MBs treatment 328 group compared (Fig. 2D, E). Two of six control (no LIUS and MBs treatment) mice developed 329 metastases, however, no instances of metastasis were observed in the LIUS and MBs treatment 330 group. There was no significant difference in the number of metastatic mice between the two groups 331 (Fig. S4). It was possible that the sample size was insufficient to yield more meaningful statistical 332 results. The average tumor weight was also significantly minor in the LIUS and MBs treatment 333 group compared with the control group (Fig. 2F, G). In summary, the results suggested that LIUS 334 and MBs treatment decreased tumorigenicity and metastatic potential of ovarian cancer in vivo.

3.3 LIUS combined with MBs reduced ovarian cancer metastasis in an intraperitoneal and
 hematogenous model

Transcoelomic metastasis and hematogenous metastasis are two main metastatic routes for ovarian
cancer [17, 38]. To investigate the impact of LIUS and MBs treatment on ovarian cancer metastasis
we constructed peritoneal metastasis and hematogenous metastasis mouse models. SKOV3 cells
which were treated after LIUS and MBs and then these were used to form peritoneal and

341 hematogenous metastases models (Fig. 3A, B). Bioluminescent imaging demonstrated that the cell 342 metastasis ability had decreased after LIUS and MBs treatment, especially in the hematogenous 343 metastasis model (Fig. 3C, D). In this study, there were notably less peritoneal metastases in the 344 peritoneal tumor transplant models after treatment with LIUS and MBs (Fig. 3C, Fig. S5A), and 345 almost no metastatic tumors in the lung after caudal vein injection compared to the control group 346 (Fig. 3D, Fig. S5B). The average total luminescence flux in nude mice was also quantitatively 347 analyzed, with a significant decrease observed in the LIUS and MBs treatment group compared to 348 the control group. The differences for the caudal vein injection nude mice was even more obvious 349 (Fig. 3E, F) (for peritoneal metastases: Day10:  $2.37e8 \pm 1.36e8 vs 1.01e8$ , p=0.014; Day17: 6.67e8 350  $\pm 3.91e8 vs 2.76e8 \pm 2.22e8, p=0.0064; Day24: 9.36e8 \pm 6.21e8 vs 5.88e8 \pm 6.29e8, p=1863; Day31:$  $1.61e9 \pm 1.32e9 vs 5.42e8 \pm 5.72e8$ , p=0.0225) (for hematogenous metastasis: Day10: 4.56e5  $\pm$ 351 352  $1.74e5 vs 2.11e5 \pm 1.05e5, p < 0.001;$  Day17:  $6.79e5 \pm 2.85e5 vs 4.67 \pm 1.39e5, p < 0.001;$  Day24: 353  $9.68e5 \pm 6.36e5 vs \ 3.41e5 \pm 1.72e5, p < 0.001;$  Day  $31: 1.36e6 \pm 9.38e5 vs \ 4.26e5 \pm 3.41e5, p < 0.001).$ 354 Over time, SKOV3 cells treated with LIUS and MBs demonstrated a gradual progression of 355 abdominal lesions in the peritoneal tumor transplant model, whereas no significant progression was 356 observed in the hematogenous metastatic model. For the inoculated tumors observed on day 31, 357 macroscopic observation revealed that the total number of tumor nodes were lower in the LIUS and 358 MBs treatment group (Fig. 3G-H). The number of metastatic lesions significantly decreased in LIUS 359 + MBs treatment group (intraperitoneally metastasis:  $2.83 \pm 1.33 \text{ vs} 1.33 \pm 0.52$ , p=0.028) (lung 360 metastasis:  $4.75 \pm 1.71 \text{ vs} 0.33 \pm 0.52, p < 0.001$ ), particularly in the hematogenous metastatic model. 361 This same observation was even more obvious in hematogenous metastasis nude mice (Fig. 3I-J). 362 Representative HE staining were shown in the Fig. S6A, B. These findings suggested that LIUS and 363 MBs treatment had diminished the ovarian cancer cell metastatic potential in vivo, especially the 364 hematogenous metastatic model.

# 365 3.4 LIUS combined with MBs disrupted the formation and protrusion of filopodia

Filopodia and lamellipodia on the edge of the cell are essential for cell migration, allowing it to
move forward [39, 40]. Thus, the formation of filopodia plays a critical role in cell invasion [41].
To elucidate the cellular mechanisms underlying the inhibition of ovarian cancer metastasis
following LIUS and MBs treatment, resultant alterations in filopodia and lamellipodia were

370 evaluated. Scanning electron microscopy observations of filopodia and lamellipodia in SKOV3 cells 371 are shown in Fig. 4A. Filopodia are slender, elongated structures extending from the cell membrane, 372 while lamellipodia are sheet-like protrusions on the cell surface, both composed of F-actin [42, 43]. 373 According to the scanning electron microscope image, after LIUS and MBs treatment, the filopodia 374 was almost invisible, but the lamellipodia was still visible. The changes of F-actin filopodia and 375 lamellipodia were analyzed through immunofluorescence staining (Fig. 4B). Through specific 376 staining of F-actin, LIUS and MBs treatment cells showed less  $(4.093 \pm 1.513 \text{ vs} 1.265 \pm 0.8956,$ 377 p < 0.001) and shorter (6.408 ± 2.255 vs 3.250 ± 1.602, p < 0.001) F-actin filopodia (Fig. 4C, D). 378 Interestingly, there was no statistically significant differences  $(3.333 \pm 0.7112 \text{ vs } 3.167 \pm 0.9499)$ , 379 p=0.445) observed in the F-actin lamellipodia following LIUS and MBs treatment (Fig. 4E). This 380 data therefore indicated that LIUS and MBs treatment inhibited the formation and protrusion of 381 filopodia, but had no effect on lamellipodia. Collectively, our results suggest LIUS and MBs 382 treatment has the potential to impede cell invasion and migration in ovarian cancer primarily by 383 inhibiting the formation of filopodia.

## 384 3.5 LIUS combined with MBs suppressed Cdc42 activity

385 The small GTPase Cdc42 is well known to participate in the process of cell migration [44]. As 386 Cdc42 is required for filopodia formation, achieved via its stimulation of downstream effector 387 proteins [19, 20]. This study attempted to investigate whether alterations in Cdc42 participated in 388 remodeling the filopodia after LIUS and MBs treatment. For this, we employed RNA sequencing 389 to quantify Cdc42 mRNA levels at various time points following LIUS and MBs treatment. 390 However, the findings indicated that the overall expression of Cdc42 mRNA remained unaltered 391 after LIUS and MBs treatment 3h, 6h, 12h, and 24h (Fig. 5A). Moreover, quantitative proteomic 392 analysis revealed that 6h, 12h, and 24h after LIUS and MBs treatment did not affect the protein 393 levels of Cdc42 (Fig. 5B). Cdc42, a member of the Rho family small GTPases, functions as a 394 molecular switch, governing the conversion between its inactive form (Cdc42-GDP) and active form 395 (Cdc42-GTP). It is well-established that the diverse functions of small GTPases are regulated 396 through interactions with key regulators, including guanine nucleotide exchange factors (GEFs) and 397 GTPase-activating proteins (GAPs) [45-47]. We investigated whether LIUS and MBs inhibit the development and extension of filopodia by modulating Cdc42 activity in SKOV3 cells. Proteomic 398

399 analysis of SKOV3 cells treated with LIUS and MBs revealed differential regulation of GEFs and 400 GAPs involved in Cdc42 modulation. Additionally, protein-protein interactions were observed (Fig. 5C). Proteomic heat map analysis revealed that, after LIUS and MBs treatment, GEFs (RhoGEF1, 401 402 2, 7, 10, 18) and GAPs (RhoGAP1, 12, 17, 29, 35) formed small clusters, with a significant increase 403 at 6 hours, followed by a gradual decrease at 12 and 24 hours (Fig. 5D, E). It is suggested that LIUS 404 and MBs treatment induces complex regulatory processes within the SKOV3 cells, which may 405 influence the activity of CDC42. The total cellular level of Cdc42 protein, regardless of treatment 406 with LIUS and MBs remained nearly unchanged as confirmed by western blot analysis. To test 407 whether LIUS and MBs treatment affected the activation status of Cdc42, Cdc42GTP levels were 408 measured before and after LIUS and MBs treatment. The data demonstrated a dramatic decrease in 409 active Cdc42 resulting from LIUS and MBs treatment compared with the controlled group (Fig. 410 5F). Active Cdc42 can transmit the signal to the downstream cascades promote filopodia formation 411 and mediate cell motility [48]. The findings suggested that LIUS and MBs could regulate Cdc42 412 activity and lead to the decrease of Cdc42 activity (Fig. 5G).

# 3.6 Cdc42CA rescued the migration and invasion via filopodia formation in LIUS combined with MBs treated SKOV3 cells

415 In cancer, the activation of Cdc42 is frequently linked to aggressive characteristics such as enhanced 416 cell movement and invasion [49]. To elucidate if Cdc42 activity was crucial to the filopodia 417 suppressor function of LIUS combined with MBs treatment, Cdc42CA overexpression was then 418 applied to in SKOV3 cells (Fig. 6B). The decreased filopodia number and length by LIUS combined 419 with MBs exposure was indeed rescued by Cdc42CA overexpression (Fig. 6A). These data 420 demonstrated that LIUS combined with MBs treatment suppresses the formation of filopodia by 421 preventing Cdc42 activation in SKOV3 cells (Fig. 6C, D). To assess whether LIUS and MBs-422 mediated Cdc42 activation affected cell migration and invasion, we examined the migration and 423 invasion abilities of SKOV3 cells following the overexpression of Cdc42CA. The results of the 424 wound healing assay showed that overexpression of Cdc42CA enhanced the migration of SKOV3 425 cells. LIUS combined with MBs treatment can inhibit this enhancement. However, the inhibitory 426 effect of LIUS and MBs is rescued by the overexpression of CDC42CA (Fig. 6E). In the transwell 427 migration (Fig. 6F) and invasion (Fig. 6G) assay were also performed to explore the migration and

428 invasion ability of SKOV3 cells upon overexpression of Cdc42CA. Again, we found that the 429 migration and invasion ability of SKOV3 cells was significantly increased after overexpressing 430 Cdc42CA. To investigate if Cdc42 was crucial to the metastasis suppressor function of LIUS 431 combined with MBs, the inhibited SKOV3 cells migration and invasion via LIUS combined with 432 MBs exposure was examined under Cdc42CA overexpression. In the transwell assay such 433 suppression via LIUS combined with MBs treatment was then confirmed to be negated and 434 migration and invasion properties confirmed to be rescued via Cdc42CA overexpression (Fig.6F, 435 G). These data showed that the negation of LIUS combined with MBs of Cdc42 is critical to LIUS 436 combined with MBs induced SKOV3 cell migration and invasion reduction.

## 437 4. Discussion

LIUS and MBs is regarded as an adjuvant therapy for cancer [13, 50]. Experimental data from 438 439 numerous in vivo and in vitro studies has demonstrated the synergistic effect when LIUS and MBs 440 treatment is incorporated with other treatments where enhanced effectiveness (from 20-80%), 441 inhibition of tumor metastasis, and extended survival are all noted in animal models [51, 52]. 442 Clinical studies (NCT03458975, NCT03199274, NCT03385200) on patients with unresectable liver 443 cancer, liver metastases, and breast cancer have also exhibited promising results. In this study, the 444 LIUS treatment device was custom-designed and built by our team, with the parameters carefully 445 optimized to prevent damage to normal cells while generating sufficient intensity to induce Cdc42 446 activation, thereby inhibiting filopodia-mediated tumor metastasis.

447 Over recent years, significant attention has been directed towards research upon mechanisms of 448 tumor effectiveness including aspects of apoptosis [53], tumor vascular shutdown [54], immune 449 response [55, 56], cellular drug uptake [57], and techniques that direct permanent damage to cancer 450 cells [58, 59], all of which are potentially impacted by LIUS and MBs treatment. Recently, Itziar 451 González et al. reported that ultrasound irradiation inhibited pancreatic cancer cell migration in 452 monolayer in vitro experiments. Their study indicates that ultrasound's impact on tumor cell 453 invasion may result from direct mechanical forces or cavitation [15]. In this study, we utilized three 454 distinct models: orthotopic, intraperitoneal metastatic, and hematogenous metastatic nude mouse 455 models, to assess the spatiotemporal effects of LIUS and MBs on ovarian cancer metastasis in vivo. 456 Compared to the intraperitoneal metastatic model, the results demonstrated a more pronounced

457 inhibitory effect of LIUS and MBs in both the orthotopic and hematogenous metastatic models. The 458 tumor in the orthotopic model is likely confined to the ovary, representing an early stage of ovarian 459 cancer. Moreover, repeated administration of LIUS and MB treatments appears to exert a 460 cumulative inhibitory effect on tumor metastasis. These findings suggest a potential therapeutic 461 strategy for early-stage ovarian cancer or for managing unresectable residual lesions post-surgery 462 in clinical settings. LIUS and MBs exposure significantly reduced the ability of SKOV3 cells to 463 traverse the bloodstream, although the effect on abdominal cavity implantation was relatively 464 modest. This may be attributed to the cytotoxic activity of innate immune cells in the bloodstream 465 targeting SKOV3 cells following treatment with LIUS and MBs. This indicated that the combination 466 of LIUS and MBs in immunotherapy may have a synergistic effect in inhibiting ovarian cancer 467 metastasis. Collectively, these findings highlight the promising potential of combining LIUS and 468 MBs as an effective therapeutic strategy for inhibiting ovarian cancer metastasis, particularly in 469 early-stage disease and in cases with residual lesions following surgery. Moreover, combining with 470 other treatments, such as immunotherapy, may lead to enhanced therapeutic outcomes.

471 A few previous studies have associated LIUS and MBs stimulation with effects upon intracellular 472 fine structures and endogenous gene/protein expression [22, 37, 60], with a particular focus upon 473 clarifying the mechanisms underlying the inhibition of cancer metastasis. In this, the increased 474 number of filopodia in tumor cells has been recognized as a critical characteristic of disease 475 progression, as reported in studies ranging from those from ovarian cancer, breast cancer, small cell 476 lung cancer, to colon cancer [61, 62]. The core structure of filopodia, the F-actin cytoskeleton, is 477 essential for processes such as cell motility, invasion, and metastasis [41]. The F-actin cytoskeleton 478 functions as a mechanosensitive sub-cellular organelle. LIUS and MBs stimulates cycles of stretch 479 and release in the cell membranes and in the cytoskeleton. These can activate mechano-sensitive 480 proteins and/or increase membrane permeability [28, 63, 64]. In this study, we observed a decrease 481 in filopodia length and quantity after LIUS and MBs treatment. This could potentially contribute to 482 the suppression of tumor metastasis. These findings suggested that LIUS and MBs treatment, 483 mediated by the regulation of the cytoskeleton, may induce alterations in the morphology and 484 quantity of filopodia. Despite this, it was interesting that the number of lamellipodia remained 485 constant. This may be due to the ultrasound intensity being insufficient to induce changes in 486 lamellipodia. Alternatively, lamellipodia may be insensitive to the mechanical stimuli caused by487 LIUS-induced MBs oscillations.

488 At the molecular level, we conducted an in-depth investigation of Cdc42, a key regulator of 489 filopodia [65]. Our findings indicated that while the expression levels of Cdc42 remained unchanged 490 at both the transcriptional and protein levels, there was a notable reduction in its active form. The 491 activity of Cdc42 proteins is determined by the GTP/GDP binding state as regulated by the guanine 492 nucleotide exchange factors (GEFs)/GTPase-activating proteins (GAPs) [66-69]. When Cdc42 is 493 activated thus facilitating the activation of the downstream cytoskeletal proteins or regulatory 494 proteins. This subsequently promotes actin polymerization [70, 71]. Our results of the inhibition of 495 filopodia formation were therefore attributable to a decrease in active Cdc42. In this investigation, 496 this was particularly confirmed where the over expression Cdc42CA could partially restore the 497 length and number of filopodia, as well as the ability of cell migration and invasion after LIUS and 498 MBs treatment. Taken together, this study strongly supports the understanding that LIUS and MBs 499 may impede the formation and protrusion of filopodia through the inhibition of Cdc42 activity, 500 thereby ultimately suppressing the metastasis of ovarian cancer. The interaction between LIUS and 501 MBs induces a moderate degree of MBs deformation, which is unlikely to cause significant direct 502 damage to cells or DNA, but may influence post-translational modifications of proteins, such as 503 phosphorylation. Further investigation into the more complex mechanisms underlying tumor inhibition by LIUS and MBs is warranted. This seems likely as derived from the results of this 504 505 present study, where LIUS and MBs treatment potentially inhibited the formation of filamentous 506 pseudopodia by downregulating Cdc42 activity, thereby achieving the desired effect of impeding 507 ovarian cancer metastasis. Overall, in this study we present evidence for a novel mechanism of LIUS 508 and MBs treatment for the inhibition of ovarian cancer metastasis.

Despite the novelty of our findings, several important issues remain to be addressed. The sample size in this study is limited, particularly with regard to in orthotopic models. Additionally, the relatively short observation period and the low incidence of metastases in the untreated group may limit the ability to draw more robust conclusions. More animal models and longer observations, as well as multiple animals, are needed to further validate the role of LIUS+MBs in inhibiting ovarian cancer metastasis in future studies. While LIUS and MBs hold promise as adjunct therapies for 515 tumors, there are still several challenges that need to be resolved before they can be widely translated 516 into clinical practice. As a form of physical stimulation, ultrasound can induce a broad range of bioeffects. Warranting further investigation should focus on understanding the mechanisms 517 518 underlying signal transduction via mechanical stimulation of cell membranes, as well as the 519 intercellular communication processes involved. Moreover, the bioeffects of ultrasound may vary 520 depending on specific parameters, and the findings of this study, which were conducted in nude 521 mice, may not be directly applicable to humans without adjustments to the experimental parameters. 522 Additionally, the deep location of the ovaries and the complexity of surrounding tissues present 523 significant challenges, particularly when dealing with residual lesions that are not amenable to surgical resection. Developing strategies to inhibit tumor metastasis while sparing normal tissues 524 525 remains a critical issue to be addressed in future research.

## 526 5. Conclusions

This study validated the inhibitory effect of LIUS combined with MBs on ovarian cancer metastasis using three models: the orthotopic ovarian cancer model, the abdominal metastasis model, and the hematogenous metastasis model. This inhibitory effect on the metastasis of ovarian cancer cells is achieved by altering the morphology and function of filopodia through the inhibition of Cdc42 activity via LIUS combined with MBs treatment (Fig.7). In general, this approach holds promise for the targeted inhibition of unresectable ovarian cancer and may be applicable to other tumor types, thereby offering new strategies for the clinical treatment of metastasis.

534

## 535 CRediT authorship contribution statement

XL: Conceptualization, methodology, data curation, formal analysis, funding acquisition, writingoriginal draft. CT: visualization, formal analysis. XF: western blot, formal analysis. JQ: SEM,
methodology, funding acquisition. WS: investigation. ZX: validation. XW: conceptualization,
methodology. YZ: Conceptualization, methodology, writing-review and editing. XL:
conceptualization. LS: conceptualization. JQ: conceptualization, methodology, writing-review and
editing, funding acquisition.

542 Funding

- 543 This work was supported by the Natural Foundation Exploration Project of Zhejiang Province
- 544 (LY22H180009), the National Natural Science Foundation of China (82471986, 82171939,
- 545 W2421099, and 82202158), the Medical and Health research project of Zhejiang Province
- 546 (2022KY357).

### 547 Declaration of competing interest

- 548 The authors declare that they have no known competing financial interests or personal relationships
- that could have appeared to influence the work reported in this paper.
- 550 **Data availability**
- 551 Data will be made available on request.
- 552 Ethics approval and consent to participate
- 553 All experiments involving animals were conducted according to the ethical policies and procedures
- approved by the Ethical Committee of the Zhejiang Chinese Medical University Laboratory Animal
- 555 Research Center (No. 20230911-11).

# 556 References

- 557 [1] R.L. Siegel, A.N. Giaquinto, A. Jemal, Cancer statistics, 2024, CA Cancer J Clin, 74 (2024)
- 558 12-49.
- 559 [2] D. Jiang, Z. Niu, X. Tan, H. He, L. Ren, J. Shen, X. Zhu, P. Zhao, M. Liu, H. Chen, R. Wang,
- 560 Q. Li, G. Cao, The mortalities of female-specific cancers in China and other countries with distinct
- 561 socioeconomic statuses: A longitudinal study, J Adv Res, 49 (2023) 127-139.
- 562 [3] D.K. Armstrong, R.D. Alvarez, J.N. Bakkum-Gamez, L. Barroilhet, K. Behbakht, A. Berchuck,
- 563 L.M. Chen, M. Cristea, M. DeRosa, E.L. Eisenhauer, D.M. Gershenson, H.J. Gray, R. Grisham,
- 564 A. Hakam, A. Jain, A. Karam, G.E. Konecny, C.A. Leath, J. Liu, H. Mahdi, L. Martin, D. Matei, M.
- 565 McHale, K. McLean, D.S. Miller, D.M. O'Malley, S. Percac-Lima, E. Ratner, S.W. Remmenga, R.

- 566 Vargas, T.L. Werner, E. Zsiros, J.L. Burns, A.M. Engh, Ovarian Cancer, Version 2.2020, NCCN
- 567 Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 19 (2021) 191-226.
- 568 [4] T. Sun, Z. Zhang, L. Tian, Y. Zheng, L. Wu, Y. Guo, X. Li, Y. Li, H. Shen, Y. Lai, J. Liu, H. Cui,
- 569 S. He, Y. Ren, G. Yang, Dualistic classification of high grade serous ovarian carcinoma has its
- 570 root in spatial heterogeneity, J Adv Res, 48 (2023) 213-225.
- 571 [5] K. Kooiman, S. Roovers, S.A.G. Langeveld, R.T. Kleven, H. Dewitte, M.A. O'Reilly, J.M.
- 572 Escoffre, A. Bouakaz, M.D. Verweij, K. Hynynen, I. Lentacker, E. Stride, C.K. Holland, Ultrasound-
- 573 Responsive Cavitation Nuclei for Therapy and Drug Delivery, Ultrasound Med Biol, 46 (2020)
- 574 1296-1325.
- [6] I. Lentacker, I. De Cock, R. Deckers, S.C. De Smedt, C.T. Moonen, Understanding ultrasound
- 576 induced sonoporation: definitions and underlying mechanisms, Adv Drug Deliv Rev, 72 (2014)577 49-64.
- 578 [7] Z. Lin, L. Meng, J. Zou, W. Zhou, X. Huang, S. Xue, T. Bian, T. Yuan, L. Niu, Y. Guo, H. Zheng,
- 579 Non-invasive ultrasonic neuromodulation of neuronal excitability for treatment of epilepsy,
  580 Theranostics, 10 (2020) 5514-5526.
- 581 [8] Y. Zhang, N. Tang, L. Huang, W. Qiao, Q. Zhu, Z. Liu, Effect of diagnostic ultrasound and
- 582 microbubble-enhanced chemotherapy on metastasis of rabbit VX2 tumor, Med Phys, 48 (2021)
  583 3927-3935.
- [9] B. Kip, C.U. Tunc, O. Aydin, Triple-combination therapy assisted with ultrasound-active gold
  nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model,
  Ultrason Sonochem, 82 (2022) 105903.
- 587 [10] N. Hosano, Z. Moosavi-Nejad, T. Hide, H. Hosano, Focused shock waves and inertial

588 cavitation release tumor-associated antigens from renal cell carcinoma, Ultrason Sonochem,

589 (2024) 107078.

- 590 [11] H. Zhou, C. Zhu, Q. Zhao, J. Ni, H. Zhang, G. Yang, J. Ge, C. Fang, H. Wei, X. Zhou, K.
- 591 Zhang, Wrecking neutrophil extracellular traps and antagonizing cancer-associated
- 592 neurotransmitters by interpenetrating network hydrogels prevent postsurgical cancer relapse and
- 593 metastases, Bioact Mater, 39 (2024) 14-24.
- 594 [12] S. Kotopoulis, G. Dimcevski, O.H. Gilja, D. Hoem, M. Postema, Treatment of human
- 595 pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case
- 596 study, Med Phys, 40 (2013) 072902.
- 597 [13] G. Dimcevski, S. Kotopoulis, T. Bjånes, D. Hoem, J. Schjott, B.T. Gjertsen, M. Biermann, A.
- 598 Molven, H. Sorbye, E. McCormack, M. Postema, O.H. Gilja, A human clinical trial using
- 599 ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer,
- 600 J Control Release, 243 (2016) 172-181.
- 601 [14] Y.J. Wang, Y. Li, K. Yan, L. Shen, W. Yang, J.F. Gong, K. Ding, Clinical study of ultrasound
- and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive
- 603 system, Chinese J Cancer Res, 30 (2018) 553-563.
- 604 [15] I. Gonzalez, J. Luzuriaga, A. Valdivieso, M. Candil, J. Frutos, J. Lopez, L. Hernandez, L.
- Rodriguez-Lorenzo, V. Yague, J.L. Blanco, A. Pinto, J. Earl, Low-intensity continuous ultrasound
- to inhibit cancer cell migration, Front Cell Dev Biol, 10 (2022) 842965.
- 607 [16] D.X. Nguyen, P.D. Bos, J. Massague, Metastasis: from dissemination to organ-specific
  608 colonization, Nat Rev Cancer, 9 (2009) 274-284.
- 609 [17] M. Yousefi, S. Dehghani, R. Nosrati, M. Ghanei, A. Salmaninejad, S. Rajaie, M. Hasanzadeh,

- A. Pasdar, Current insights into the metastasis of epithelial ovarian cancer hopes and hurdles,
- 611 Cell Oncol (Dordr), 43 (2020) 515-538.
- 612 [18] K.M. Alblazi, C.H. Siar, Cellular protrusions--lamellipodia, filopodia, invadopodia and
- 613 podosomes--and their roles in progression of orofacial tumours: current understanding, Asian
- 614 Pac J Cancer Prev, 16 (2015) 2187-2191.
- [19] A. Hall, Rho GTPases and the actin cytoskeleton, Science, 279 (1998) 509-514.
- [20] S. Etienne-Manneville, Cdc42--the centre of polarity, J Cell Sci, 117 (2004) 1291-1300.
- 617 [21] S. Etienne-Manneville, A. Hall, Rho GTPases in cell biology, Nature, 420 (2002) 629-635.
- 618 [22] Y. Song, J. Chen, C. Zhang, L. Xin, Q. Li, Y. Liu, C. Zhang, S. Li, P. Huang, Mechanosensitive
- 619 channel Piezo1 induces cell apoptosis in pancreatic cancer by ultrasound with microbubbles,
- 620 iScience, 25 (2022) 103733.
- 621 [23] J. Du, L. Zheng, P. Gao, H. Yang, W.J. Yang, F. Guo, R. Liang, M. Feng, Z. Wang, Z. Zhang,
- L. Bai, Y. Bu, S. Xing, W. Zheng, X. Wang, L. Quan, X. Hu, H. Wu, Z. Chen, L. Chen, K. Wei, Z.
- 623 Zhang, X. Zhu, X. Zhang, Q. Tu, S.M. Zhao, X. Lei, J.W. Xiong, A small-molecule cocktail promotes
- mammalian cardiomyocyte proliferation and heart regeneration, Cell Stem Cell, 29 (2022) 545558 e513.
- 626 [24] J.C. Thiele, M. Jungblut, D.A. Helmerich, R. Tsukanov, A. Chizhik, A.I. Chizhik, M.J.
- 627 Schnermann, M. Sauer, O. Nevskyi, J. Enderlein, Isotropic three-dimensional dual-color super-
- 628 resolution microscopy with metal-induced energy transfer, Sci Adv, 8 (2022) eabo2506.
- [25] Y. Werner, E. Mass, P. Ashok Kumar, T. Ulas, K. Handler, A. Horne, K. Klee, A. Lupp, D.
- 630 Schutz, F. Saaber, C. Redecker, J.L. Schultze, F. Geissmann, R. Stumm, Cxcr4 distinguishes
- 631 HSC-derived monocytes from microglia and reveals monocyte immune responses to

- experimental stroke, Nat Neurosci, 23 (2020) 351-362.
- 633 [26] A.R. Young, M. Narita, M. Ferreira, K. Kirschner, M. Sadaie, J.F. Darot, S. Tavare, S. Arakawa,
- 634 S. Shimizu, F.M. Watt, M. Narita, Autophagy mediates the mitotic senescence transition, Genes
- 635 Dev, 23 (2009) 798-803.
- 636 [27] S. Hu, K. Meng, T. Wang, R. Qu, B. Wang, Y. Xi, T. Yu, Z. Yuan, Z. Cai, Y. Tian, C. Zeng, X.
- 637 Wang, W. Zou, X. Fu, L. Li, Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes
- 638 murine lung tumors to anti-PD-L1 therapy, Biomark Res, 12 (2024) 40.
- [28] E.F. Schibber, D.R. Mittelstein, M. Gharib, M.G. Shapiro, P.P. Lee, M. Ortiz, A dynamical
- 640 model of oncotripsy by mechanical cell fatigue: selective cancer cell ablation by low-intensity
- 641 pulsed ultrasound, Proc Math Phys Eng Sci, 476 (2020) 20190692.
- 642 [29] G. Fan, J. Qin, X. Fu, X. Si, L. Li, K. Yang, B. Wang, H. Lou, J. Zhu, Low-Intensity Focused
- 643 Ultrasound Targeted Microbubble Destruction Enhanced Paclitaxel Sensitivity by Decreasing
- 644 Autophagy in Paclitaxel-Resistant Ovarian Cancer, Front Oncol, 12 (2022) 823956.
- [30] L. Wang, X. Li, F. Gao, Y. Liu, S. Lang, C. Wang, D. Zhang, Effect of ultrasound combined
- 646 with exogenous GABA treatment on polyphenolic metabolites and antioxidant activity of mung
- bean during germination, Ultrason Sonochem, 94 (2023) 106311.
- [31] K. Saito, K. Miyake, P.L. McNeil, K. Kato, K. Yago, N. Sugai, Plasma membrane disruption
- underlies injury of the corneal endothelium by ultrasound, Exp Eye Res, 68 (1999) 431-437.
- [32] T. Bjanes, S. Kotopoulis, E.T. Murvold, T. Kamceva, B.T. Gjertsen, O.H. Gilja, J. Schjott, B.
- Riedel, E. McCormack, Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to
  Pancreatic Cancer Cells, Pharmaceutics, 12 (2020).
- [33] M. Du, T. Wang, W. Peng, R. Feng, M. Goh, Z. Chen, Bacteria-driven nanosonosensitizer

- 654 delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced
- immunogenic cell death, J Nanobiotechnology, 22 (2024) 167.
- 656 [34] Y. Zhao, D. Shi, L. Guo, M. Shang, X. Sun, D. Meng, S. Xiao, X. Wang, J. Li, Ultrasound
- 657 targeted microbubble destruction-triggered nitric oxide release via nanoscale ultrasound
- 658 contrast agent for sensitizing chemoimmunotherapy, J Nanobiotechnology, 21 (2023) 35.
- [35] R.Y. Huang, Y.H. Lin, S.Y. Lin, Y.N. Li, C.S. Chiang, C.W. Chang, Magnetic ternary
- 660 nanohybrids for nonviral gene delivery of stem cells and applications on cancer therapy,
- 661 Theranostics, 9 (2019) 2411-2423.
- 662 [36] S. Orsulic, Y. Li, R.A. Soslow, L.A. Vitale-Cross, J.S. Gutkind, H.E. Varmus, Induction of
- ovarian cancer by defined multiple genetic changes in a mouse model system, Cancer Cell, 1
  (2002) 53-62.
- [37] Y. He, X.H. Dong, Q. Zhu, Y.L. Xu, M.L. Chen, Z. Liu, Ultrasound-triggered microbubble
- 666 destruction enhances the radiosensitivity of glioblastoma by inhibiting PGRMC1-mediated
- autophagy in vitro and in vivo, Mil Med Res, 9 (2022) 9.
- 668 [38] S. Pradeep, S.W. Kim, S.Y. Wu, M. Nishimura, P. Chaluvally-Raghavan, T. Miyake, C.V.
- 669 Pecot, S.J. Kim, H.J. Choi, F.Z. Bischoff, J.A. Mayer, L. Huang, A.M. Nick, C.S. Hall, C. Rodriguez-
- 670 Aguayo, B. Zand, H.J. Dalton, T. Arumugam, H.J. Lee, H.D. Han, M.S. Cho, R. Rupaimoole, L.S.
- Mangala, V. Sehgal, S.C. Oh, J. Liu, J.S. Lee, R.L. Coleman, P. Ram, G. Lopez-Berestein, I.J.
- Fidler, A.K. Sood, Hematogenous metastasis of ovarian cancer: rethinking mode of spread,
- 673 Cancer Cell, 26 (2014) 77-91.
- 674 [39] T.D. Pollard, G.G. Borisy, Cellular motility driven by assembly and disassembly of actin
- 675 filaments, Cell, 112 (2003) 453-465.

- [40] E.S. Chhabra, H.N. Higgs, The many faces of actin: matching assembly factors with cellular
- 677 structures, Nat Cell Biol, 9 (2007) 1110-1121.
- 678 [41] G. Jacquemet, H. Hamidi, J. Ivaska, Filopodia in cell adhesion, 3D migration and cancer cell
- 679 invasion, Curr Opin Cell Biol, 36 (2015) 23-31.
- 680 [42] R. Zou, W. Shi, X. Chang, M. Zhang, S. Tan, R. Li, H. Zhou, Y. Li, G. Wang, W. Lv, X. Fan,
- 681 The DNA-dependent protein kinase catalytic subunit exacerbates endotoxemia-induced
- 682 myocardial microvascular injury by disrupting the MOTS-c/JNK pathway and inducing profilin-
- 683 mediated lamellipodia degradation, Theranostics, 14 (2024) 1561-1582.
- 684 [43] D.Y. Chen, N.H. Sun, Y.P. Lu, L.J. Hong, T.T. Cui, C.K. Wang, X.H. Chen, S.S. Wang, L.L.
- 685 Feng, W.X. Shi, K. Fukunaga, Z. Chen, Y.M. Lu, F. Han, GPR124 facilitates pericyte polarization
- and migration by regulating the formation of filopodia during ischemic injury, Theranostics, 9
- 687 (2019) 5937-5955.
- [44] N. Reymond, J.H. Im, R. Garg, F.M. Vega, B. Borda d'Agua, P. Riou, S. Cox, F. Valderrama,
- 689 R.J. Muschel, A.J. Ridley, Cdc42 promotes transendothelial migration of cancer cells through
- 690 beta1 integrin, J Cell Biol, 199 (2012) 653-668.
- [45] K. Wennerberg, K.L. Rossman, C.J. Der, The Ras superfamily at a glance, J Cell Sci, 118
  (2005) 843-846.
- [46] N. Mitin, K.L. Rossman, C.J. Der, Signaling interplay in Ras superfamily function, Curr Biol,
  15 (2005) R563-574.
- 695 [47] H. Farhan, V.W. Hsu, Cdc42 and Cellular Polarity: Emerging Roles at the Golgi, Trends Cell
  696 Biol, 26 (2016) 241-248.
- 697 [48] Y. He, D. Li, S.L. Cook, M.S. Yoon, A. Kapoor, C.V. Rao, P.J. Kenis, J. Chen, F. Wang,

- 698 Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating
- Rac/Cdc42 activity and the actin cytoskeleton, Mol Biol Cell, 24 (2013) 3369-3380.
- 700 [49] M.D.M. Maldonado, S. Dharmawardhane, Targeting Rac and Cdc42 GTPases in Cancer,
- 701 Cancer Res, 78 (2018) 3101-3111.
- [50] S. Yang, P. Wang, X.B. Wang, X.M. Su, Q.H. Liu, Activation of microbubbles by low-level
- therapeutic ultrasound enhances the antitumor effects of doxorubicin, Eur Radiol, 24 (2014)
  2739-2753.
- 705 [51] J. Qin, T.Y. Wang, J.K. Willmann, Sonoporation: Applications for Cancer Therapy, Adv Exp
- 706 Med Biol, 880 (2016) 263-291.
- 707 [52] S. Pelka, C. Guha, Enhancing Immunogenicity in Metastatic Melanoma: Adjuvant Therapies
- to Promote the Anti-Tumor Immune Response, Biomedicines, 11 (2023).
- 709 [53] L. Chen, D. Cong, Y. Li, D. Wang, Q. Li, S. Hu, Combination of sonodynamic with
- 710 temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via
- suppressing NHE-1 expression, Ultrason Sonochem, 39 (2017) 654-661.
- 712 [54] X. Zhao, C. Pellow, D.E. Goertz, Intravital imaging and cavitation monitoring of antivascular
- viltrasound in tumor microvasculature, Theranostics, 13 (2023) 250-266.
- 714 [55] A. Rix, H. Heinrichs, C. Porte, C. Leenaars, A. Bleich, F. Kiessling, Ultrasound-induced
- immune responses in tumors: A systematic review and meta-analysis, J Control Release, 371
- 716 (2024) 146-157.
- 717 [56] J. Tang, J. Tang, H. Li, J. Zhou, N. Tang, Q. Zhu, X. Wang, B. Zhu, N. Li, Z. Liu, Mechanical
- 718 destruction using a minimally invasive Ultrasound Needle induces anti-tumor immune responses
- and synergizes with the anti-PD-L1 blockade, Cancer Lett, 554 (2023) 216009.

- 720 [57] W.H. Liao, M.Y. Hsiao, Y. Kung, H.L. Liu, J.C. Bera, C. Inserra, W.S. Chen, TRPV4 promotes
- acoustic wave-mediated BBB opening via Ca(2+)/PKC-delta pathway, J Adv Res, 26 (2020) 15-
- 722 28.
- [58] L.B. Feril, Jr., K. Yamaguchi, Y. Ikeda-Dantsuji, Y. Furusawa, Y. Tabuchi, I. Takasaki, R.
- 724 Ogawa, Z.G. Cui, K. Tachibana, Low-intensity ultrasound inhibits melanoma cell proliferation in
- vitro and tumor growth in vivo, J Med Ultrason (2001), 48 (2021) 451-461.
- [59] T. Saliev, D. Begimbetova, D. Baiskhanova, D. Abetov, U. Kairov, C.P. Gilman, B.
- 727 Matkarimov, K. Tachibana, Apoptotic and genotoxic effects of low-intensity ultrasound on healthy
- and leukemic human peripheral mononuclear blood cells, J Med Ultrason (2001), 45 (2018) 31-
- 729 39.
- [60] P. Atherton, F. Lausecker, A. Harrison, C. Ballestrem, Low-intensity pulsed ultrasound
- promotes cell motility through vinculin-controlled Rac1 GTPase activity, J Cell Sci, 130 (2017)

732 2277-2291.

- [61] J.T. Groves, J. Kuriyan, Molecular mechanisms in signal transduction at the membrane, Nat
- 734 Struct Mol Biol, 17 (2010) 659-665.
- [62] T.D. Pollard, J.A. Cooper, Actin, a central player in cell shape and movement, Science, 326
  (2009) 1208-1212.
- [63] X. Chen, R.S. Leow, Y. Hu, J.M. Wan, A.C. Yu, Single-site sonoporation disrupts actin
  cytoskeleton organization, J R Soc Interface, 11 (2014) 20140071.
- 739 [64] B. Krasovitski, V. Frenkel, S. Shoham, E. Kimmel, Intramembrane cavitation as a unifying
- 740 mechanism for ultrasound-induced bioeffects, Proc Natl Acad Sci U S A, 108 (2011) 3258-
- 741 3263.

- [65] C.D. Nobes, A. Hall, Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular
- focal complexes associated with actin stress fibers, lamellipodia, and filopodia, Cell, 81 (1995)
  53-62.
- [66] P.M. Muller, J. Rademacher, R.D. Bagshaw, C. Wortmann, C. Barth, J. van Unen, K.M. Alp,
- 746 G. Giudice, R.L. Eccles, L.E. Heinrich, P. Pascual-Vargas, M. Sanchez-Castro, L. Brandenburg,
- G. Mbamalu, M. Tucholska, L. Spatt, M.T. Czajkowski, R.W. Welke, S. Zhang, V. Nguyen, T.
- 748 Rrustemi, P. Trnka, K. Freitag, B. Larsen, O. Popp, P. Mertins, A.C. Gingras, F.P. Roth, K. Colwill,
- 749 C. Bakal, O. Pertz, T. Pawson, E. Petsalaki, O. Rocks, Systems analysis of RhoGEF and RhoGAP
- regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions, Nat Cell
- 751 Biol, 22 (2020) 498-511.
- [67] H. Bagci, N. Sriskandarajah, A. Robert, J. Boulais, I.E. Elkholi, V. Tran, Z.Y. Lin, M.P. Thibault,
- 753 N. Dube, D. Faubert, D.R. Hipfner, A.C. Gingras, J.F. Cote, Mapping the proximity interaction
- network of the Rho-family GTPases reveals signalling pathways and regulatory mechanisms, Nat
- 755 Cell Biol, 22 (2020) 120-134.
- [68] Y.T. Zhou, L.L. Chew, S.C. Lin, B.C. Low, The BNIP-2 and Cdc42GAP homology (BCH) domain
- 757 of p50RhoGAP/Cdc42GAP sequesters RhoA from inactivation by the adjacent GTPase-activating
- 758 protein domain, Mol Biol Cell, 21 (2010) 3232-3246.
- 759 [69] Y. Zhou, H. Ji, Q. Xu, X. Zhang, X. Cao, Y. Chen, M. Shao, Z. Wu, J. Zhang, C. Lu, J. Yang,
- 760 Y. Shi, H. Bu, Congenital biliary atresia is correlated with disrupted cell junctions and polarity
- caused by Cdc42 insufficiency in the liver, Theranostics, 11 (2021) 7262-7275.
- 762 [70] J. Peng, B.J. Wallar, A. Flanders, P.J. Swiatek, A.S. Alberts, Disruption of the Diaphanous-
- related formin Drf1 gene encoding mDia1 reveals a role for Drf3 as an effector for Cdc42, Curr

764	Biol,	13	(2003)	534-545.
-----	-------	----	--------	----------

765 [71] M. Zhang, X. Wang, F. Guo, Q. Jia, N. Liu, Y. Chen, Y. Yan, M. Huang, H. Tang, Y. Deng, S.

767 by Regulating Intercellular Junctions and Keratinization of Epidermal Cells during Mouse Skin

768 Development, Theranostics, 9 (2019) 5065-5084.

<sup>766</sup> Huang, Z. Zhou, L. Zhang, L. Zhang, Cdc42 Deficiency Leads To Epidermal Barrier Dysfunction








Fig.1 LIUS and MBs reduced the migration and invasion of ovarian cancer cells. (A) IOSE80 cells were treated with LIUS and MBs. The percentage of cells death was then determined using flow cytometry with Calcein AM/ propidium iodide staining, ns p>0.05, \*\*p<0.01. (B) Wound healing assays showing cell migration in SKOV3 cells. (Magnification, × 100). Quantification of the wound closer rate of SKOV3 cells, n=3, ns p>0.05, \*p<0.05, \*\*p<0.01. (C) Transwell migration assays in SKOV3 cells. Cells that migrated to the outer sides of the inserts were counted in five randomly selected fields, n=3, \*\*\*p<0.001. (D) Transwell invasion assays in SKOV3 cells. The cells that invaded the outer sides of the inserts were counted in five randomly selected fields, n=3, \*\*\*p<0.001. 







816 IVIS: In vivo bioluminescent images





Fig.3 LIUS and MBs inhibition of ovarian cancer cells metastasis in peritoneal metastasis and
hematogenous metastasis nude mouse models. (A, B) Schema for representing the experimental
procedures. (C, D) *In vivo* bioluminescent images of peritoneal metastasis and hematogenous


821	metastasis of OC. (E, F) Quantification of bioluminescent in peritoneal metastasis (E) and
822	hematogenous metastasis (F), n=6, ns p>0.05, p<0.05, **p<0.01, ***p<0.001. (G) Macroscopic
823	observation of the number and range of metastatic lesions in nude mice. The red circle indicates
824	metastatic nodules. (H) Macroscopic observation of the number and range of metastatic lesions in
825	the lungs. The red circle indicates metastatic nodules. (I) The average number of peritoneal
826	metastatic nodules in nude mice, n=6, * $p$ <0.05. (J) The average number of lung metastatic nodules
827	in nude mice, n=4-6, *** <i>p</i> <0.001.
828	
829	
830	
831	
832	
833	
834	
835	
836	
837	
838	
839	
840	
841	
842	
843	
844 845	
845 846	
847	
041	






849 Fig.4 LIUS and MBs inhibited the formation and protrusion of filopodia. (A) SEM images of 850 SKOV3 cells before and after LIUS and MBs treatment 6h. Red arrows show filopodia, red asterisks 851 show lamellipodia. Scale bar =  $10 \mu m$ . (B) SKOV3 cells without and with LIUS+MBs treatment for 852 6h where immunofluorescent staining expressing F-actin (red) images were acquired. White arrows 853 showing filopodia, white asterisks showing lamellipodia. Scale bar: left figures at 10 µm, right 854 figures at 5 µm. (C-E) Histograms showing the length of filopodia, number of filopodia and 855 lamellipodia of 30 cells respectively. \*\*\*p<0.001, ns p>0.05. 856 SEM: scanning electron microscope. IF: immunofluorescent 857

- 858
- 859



861 Fig.5 LIUS and MBs inhibited the activation of Cdc42 without impacting protein quantity 862 expression. (A) Relative RNA expression level at different times of LIUS and MBs treatment. (B) 863 Relative protein expression levels at different times of LIUS and MBs treatment. (C) RhoGAP, 864 RhoGAP and Cdc42 interaction network. (D) Heat map of RhoGEFs expression level at different 865 time of ultrasonic cavitation treatment. (E) Heat map of RhoGAPs expression level at different time 866 of ultrasonic cavitation treatment. (F) Expression of Cdc42 and active Cdc42 (Cdc42GTP) both 867 without and with LIUS and MBs treatment for 6h were analyzed by Western blot. (G) Schematic 868 diagram of Cdc42 active and inactive transitions. 869



37

872	following LIUS combined with MBs. (A) SKOV3 cells transfected with either EV or Cdc42CA
873	plasmids, with or without LIUS and MBs treatment for 6 hours, were subjected to IF staining. (B)
874	Expression of SKOV3 cells were transfected with empty vectors (EV) or Cdc42 constitutively
875	activated (CA, Cdc42 G12C mutation). Histograms showing the filopodia length (C) and the number
876	(D) of filopodia per 30 cells, respectively. *p < 0.05, ***p < 0.001. (E) Cdc42CA overexpression
877	rescued the SKOV3 cells migration inhibition via LIUS and MBs. Quantification of the wound
878	closer rate of SKOV3 cells. n=3, ***p<0.001. (F) Transwell migration assay showed that Cdc42CA
879	overexpression rescued the inhibition of SKOV3 cell migration induced by LIUS and MBs.
880	Quantification of the wound closer rate of SKOV3 cells. n=3, ***p<0.001. (G) Overexpression of
881	Cdc42CA reversed the inhibition of SKOV3 cell invasion induced by LIUS and MBs.
882	Quantification of the wound closer rate of SKOV3 cells. n=3, ***p<0.001.
883	
884	
885	
886	
887	
888	
889	
890	
891	
892	
893	
894	
895	
896	
897	
898	






Fig.7 Schematic illustration the potential mechanism of LIUS combined with MBs inhibiting
ovarian cancer metastasis. CDC42 GTPases operate as switches between inactive GDP-bound and
active GTP-bound forms. In its GTP-bound state, Cdc42 activates downstream effectors, thereby
inducing filopodia formation through the bundling of F-actin. LIUS and MBs treatment reduction
of this activity leads to unregulated signaling finally hindering filopodia formation and inhibiting
ovarian cancer metastasis.